MTFR2

Across TCGA pan-cancer cohorts, MTFR2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MTFR2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MTFR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTFR2 expression acts as an unfavorable survival marker.

KIRP, LUSC, and UCEC are the cancer types where MTFR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.148	0.904	<.001	30	view →
LUSC	OS	Median	All	0.133	0.776	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MTFR2–KIRP (OS)

Open the KIRP breakdown →